| URL | https://bioprocessintl.com/bioprocess-insider/faci |
| Source | Bio Process International |
| Date Published | 10/24/2022 |
| Author Name | Dan Stanton |
| Mentions specific company case(s) of reshoring, kept from offshoring, or transplant | Yes |
| Company/Division name | Triumvira Immunologics Inc. |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Year reshoring announced: | 2022 |
| City reshored to: | San Francisco, |
| State(s) reshored to: | CA |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | T-cell, cell therapy |
| What domestic positive factors made reshoring more attractive? | Skilled workforce availability/training, Under-utilized capacity |